Breanne Briskey
Psychiatry · Wheaton, ILNPI 1962668582
Payments from drug & device makers
Across 170 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$696
- Johnson & Johnson$267
- Lundbeck LLC$255
- Corium, LLC$251
- Otsuka America Pharmaceutical, Inc.$196
- Takeda Pharmaceuticals U.S.A., Inc.$141
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,083100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 45 | $696 |
| Johnson & Johnson | 9 | $267 |
| Lundbeck LLC | 20 | $255 |
| Corium, LLC | 15 | $251 |
| Otsuka America Pharmaceutical, Inc. | 10 | $196 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $141 |
| Alkermes, Inc. | 4 | $130 |
| Sunovion Pharmaceuticals Inc. | 7 | $125 |
| Vanda Pharmaceuticals Inc. | 5 | $123 |
| Shire North American Group Inc | 8 | $120 |
| Axsome Therapeutics, Inc. | 5 | $117 |
| Ironshore Pharmaceuticals Inc. | 5 | $101 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $88 |
| Avanir Pharmaceuticals, Inc. | 4 | $65 |
| Teva Pharmaceuticals USA, Inc. | 3 | $57 |
| Neurocrine Biosciences, Inc. | 3 | $54 |
| Supernus Pharmaceuticals, Inc. | 2 | $44 |
| Bausch Health US, LLC | 2 | $36 |
| Almatica Pharma LLC | 1 | $30 |
| Neos Therapeutics, LP | 2 | $27 |
| Collegium Pharmaceutical, Inc. | 1 | $25 |
| Tris Pharma Inc | 1 | $23 |
| Biogen | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Adlon Therapeutics L.p. | 1 | $15 |
| OWP Pharmaceuticals, Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $11 |
| Neuronetics, Inc. | 1 | $9 |
How this compares
$3,083 in reported general payments places this provider in the 85th percentile of 1,344 psychiatry providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 19 | $398 |
| Clonazepam | 12 | $205 |
| Gabapentin | 22 | $198 |
| Bupropion XlBupropion Hcl | 24 | $162 |
| Sertraline Hcl | 16 | $115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $30 | $11516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Wheaton
- Syed AliWheaton$31K
- Jeffrey RossNorthbrook$10.8M
- Yuhwen ChowChicago$8.5M
- Mark LermanNorthbrook$4.5M
- Danesh AlamWinfield$2.7M
- John ZajeckaSkokie$2.5M
- Riaz BaberNaperville$2.4M
- Michael GreenbaumLibertyville$2.2M
- Sandeep GaonkarNaperville$1.8M
- Jon GrantChicago$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.